Abstract: The present invention provides a method for efficiently obtaining a complex in which a gene (mRNA) and a peptide as a translation product thereof are linked via a peptide receptor molecule, and utilization thereof. In the method of the present invention, at least one 2?-modified nucleoside derivative is introduced into a 5? end side of an antisense strand of a template DNA.
Abstract: The present invention provides a novel class of insecticides for control of disease vector insects, particularly mosquitoes. These insecticides prevent maturation or development of larvae into adult insects using interfering RNA (iRNA). The present invention further includes compositions comprising iRNA and methods of controlling, reducing, or treating an insect infestation with the iRNA or compositions described herein.
Type:
Grant
Filed:
July 13, 2017
Date of Patent:
February 22, 2022
Assignees:
Indiana University Research and Technology Corporation, University of Notre Dame Du Lac
Inventors:
Molly Duman Scheel, David W. Severson, Kathleen Eggleson, Na Wei
Abstract: Disclosed are a pharmaceutical composition for anionic drug delivery, and a preparation method therefor, the pharmaceutical composition for anionic drug delivery containing: an anionic drug as an active ingredient; a cationic compound; an amphiphilic block copolymer; and a polylactate, wherein the anionic drug formed a complex with the cationic lipid, and the complex is encapsulated within a micelle structure formed by the amphiphilic block copolymer and the polylactate.
Type:
Grant
Filed:
September 12, 2016
Date of Patent:
February 22, 2022
Inventors:
Hye Yeong Nam, Bong-Oh Kim, Min-Hyo Seo, Ji-Yeon Son, Ji-Hye Choi, Sang Hoon Kim
Abstract: Methods of prohibiting Xist-dependent silencing of X chromosome genes include targeting the required Xist silencing complex components including SHARP, SMRT, HDAC3, SAF-A, LBR, and the respective binding sites of SHARP, LBR, and SAF-A on Xist, thereby prohibiting Xist repression, allowing for reactivation of the silenced X chromosome genes.
Type:
Grant
Filed:
April 25, 2016
Date of Patent:
February 15, 2022
Assignee:
California Institute of Technology
Inventors:
Mitchell Guttman, Chun-Kan Chen, Colleen A. McHugh
Abstract: The present invention relates to recombinant adeno-associated virus (rAAV) delivery of polynucleotides for treating Duchenne Muscular Dystrophy resulting from the duplication of DMD exon 2. The invention provides rAAV products and methods of using the rAAV in the treatment of Duchenne Muscular Dystrophy.
Type:
Grant
Filed:
July 11, 2018
Date of Patent:
January 25, 2022
Assignee:
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
Inventors:
Kevin Flanigan, Adeline Vulin-Chaffiol, Nicolas Wein
Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
January 4, 2022
Assignee:
Ionis Pharmaceuticals, Inc.
Inventors:
Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
Abstract: An objective of the present invention is to provide a chemically-modified siRNA that has polydeoxyadenylic acid added to the 5? end of the sense strand, and, when complexed with schizophyllan, is high in resistance against RNase and moreover effectively exhibits RNAi activity. To achieve the objective, in the chemically-modified siRNA with polydeoxyadenylic acid added to the 5? end of the sense strand, specific chemical modification is performed for dinucleotide sequences of CA, UA, and UG in the base sequence of the sense strand and dinucleotide sequences of CA, UA, and UG in the base sequence at and after the eighth base from the 5? end of the antisense strand.
Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
Type:
Grant
Filed:
February 5, 2020
Date of Patent:
December 14, 2021
Assignee:
THERMO FISHER SCIENTIFIC INC.
Inventors:
Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
Abstract: Disclosed herein are UBAP2L targeting agents and use of such agents for the treatment of a neurodegenerative disorder. Further disclosed herein are methods of monitoring the progression of a neurodegenerative disorder and methods of determining the efficacy of a neurodegenerative disorder therapy.
Type:
Grant
Filed:
June 4, 2019
Date of Patent:
December 14, 2021
Assignee:
The Regents of the University of California
Inventors:
Eugene Yeo, Sebastian Markmiller, En-Ching Luo
Abstract: The present invention generally relates to bacterial polypeptide display systems, libraries using these bacterial display systems, and methods of making and using these systems, including methods for improved display of polypeptides on the extracellular surface of bacteria using circularly permuted transmembrane bacterial polypeptides that have been modified to increase resistance to protease degradation and to enhance polypeptide display characteristics.
Type:
Grant
Filed:
March 2, 2020
Date of Patent:
December 14, 2021
Assignee:
CytomX Therapeutics, Inc.
Inventors:
Sherry Lynn La Porte, Stephen James Moore, James William West
Abstract: Codon optimized nucleic acid sequences for RDH12 are provided, as well as recombinant viral vectors, such as AAV, expression cassettes, proviral plasmids or other plasmids containing the codon optimized sequence for functional RDH12. Recombinant vectors are provided that express the codon optimized, functional RDH12. Compositions containing these codon optimized sequences are useful in methods for treating, retarding or halting certain blinding diseases resulting from the absence, deficiency or inappropriate expression of RDH12. Other compositions and methods are providing for correcting a non-functional, defective or inadequately expressed native RDH12.
Type:
Grant
Filed:
July 7, 2017
Date of Patent:
December 14, 2021
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Jean Bennett, Junwei Sun, Vidyullatha Vasireddy
Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
Abstract: Provided herein, in some embodiments, are artificial ribosomes that synthesize nonribosomal peptides, polyketides, and fatty acids with full control over peptide sequence. Also provided herein are methods for programmed synthesis of nonribosomal peptides, polyketides, and fatty acids. In particular, provided herein are methods for scalable synthesis of a wide range of antibacterial, antifungal, antiviral, and anticancer compounds.
Type:
Grant
Filed:
January 11, 2019
Date of Patent:
November 30, 2021
Assignee:
Arizona Board of Regents on behalf of Arizona State University
Abstract: An object of the present invention is to provide ASO that can effectively suppress a formation of RNA foci spontaneously occurring in neurons having SCA36 mutation, without inducing the cleavage of NOP56 pre-mRNA. The present invention provides an oligonucleotide comprising a nucleotide sequence in which one or more nucleotide sequences represented by SEQ ID NO: 2 are consecutively connected and is complementary to pre-mRNA of NOP56 gene, wherein a structure formed by the hybridization of the oligonucleotide to the pre-mRNA is resistant to RNaseH.
Abstract: A method for displaying proteins and peptides is disclosed in which individual proteins or peptides remain associated with the DNA encoding them. Proteins or peptides can be generated by in vitro translation of DNA templates, either free in solution or arrayed on a solid support, such that the proteins or peptides remain immobilized on their DNA templates. In particular, high throughput sequencing can be combined with high throughput functional characterization of encoded proteins and peptides, wherein the identity of each protein or peptide is determined by DNA sequencing, and functional studies are carried out directly on each protein or peptide while immobilized on the DNA template encoding it. The methods of the invention should find numerous applications, for example, in high throughput genetic or pharmacological screening, epitope mapping, and protein engineering and directed evolution.
Type:
Grant
Filed:
August 12, 2019
Date of Patent:
November 16, 2021
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
Type:
Grant
Filed:
December 20, 2017
Date of Patent:
November 2, 2021
Assignees:
Ionis Pharmaceuticals, Inc, The Regents of the University of California, Ludwig Institute for Cancer
Inventors:
C. Frank Bennett, Frank Rigo, Don W. Cleveland, Clotilde Lagier-Tourenne, John M. Ravits, Michael W. Baughn
Abstract: The present invention provides methods and compositions for stable genetic modification of cultured mammalian cells. The genetic modifications can be used to produce cultured mammalian cells for therapeutic or diagnostic purposes.
Type:
Grant
Filed:
May 11, 2020
Date of Patent:
November 2, 2021
Assignee:
DNA TWOPOINTO INC.
Inventors:
Jeremy Minshull, Maggie Lee, Varsha Sitaraman, Ferenc Boldog
Abstract: Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification 5 conferring stability to the RNA, as well as related methods, are disclosed.
Type:
Grant
Filed:
March 27, 2018
Date of Patent:
October 5, 2021
Assignee:
TRANSLATE BIO, INC.
Inventors:
Braydon Charles Guild, Michael Heartlein, Frank DeRosa